It ’s not gonna’ kill you to take hormone replacement
It’s not going to kill you to take hormone replacement therapy. That’s the take home message from the latest analysis of the Women’s Health Initiative, the largest and longest randomized trial of hormone replacement therapy (HRT) in menopausal women. After almost 18 years of follow up in the WHI, there was no increase in overall mortality, including death rates from cancer, in women taking HRT for up to 5.6 years (estrogen plus progestin) or 7.2 years (estrogen alone). There was a non-significant reduction in mortality among those who started HRT between ages 50 and 59, the group most likely to be prescribed hormone therapy for menopausal symptoms. I’ve blogged before about the results and limitations of the WHI, which found, on balance, that the health risks of HRT (breast cancer, blood clots, stroke) about equaled its health benefits (protection against colon cancer and osteoporosis) in women staring HRT on average 10 years after the onset of menopause. The study (and the US Preventive Services Task Force) concluded that there was no reason for women to take HRT for preventive health reasons. The biggest criticism of the WHI was that it did not include women most likely to benefit from taking HRT – those with hot flashes, night sweats, insomnia and other menopausal symptoms. These women start HRT at menopause, not 10 years after it’s over. In this younger group, more recent research suggests there may be a reduction in heart dis...
In this study, we use ChIP-Seq to identify Dppa4 binding genome-wide in three distinct cell types: mouse embryonic stem cells (mESC), embryonal carcinoma cells, and 3T3 fibroblasts ectopically expressing Dppa4. We find a core set of Dppa4 binding sites shared across cell types, and also a substantial number of sites unique to each cell type. Across cell types Dppa4 shows a preference for binding to regions with active chromatin signatures, and can influence chromatin modifications at target genes. In 3T3 fibroblasts with enforced Dppa4 expression, Dppa4 represses the cell cycle inhibitor Cdkn2c and activates Ets family tra...
Conclusions: LUCAT1 was upregulated in ccRCC tissues and renal cancer cell lines, and significantly correlated with malignant stage and poor prognosis in ccRCC. LUCAT1 promoted proliferation and invasion in ccRCC cells through the AKT/GSK-3 β signaling pathway. We also revealed that LUCAT1 overexpression was induced by chemokine CXCL2. These findings indicate that the CXCL2/LUCAT1/AKT/GSK-3β axis is a potential therapeutic target and molecular biomarker for ccRCC.Cell Physiol Biochem 2018;48:891 –904
Conclusion: Our results have revealed a novel mechanism by which ALKBH5 inhibits pancreatic cancer motility by demethylating lncRNA KCNK15-AS1, identifying a potential therapeutic target for pancreatic cancer.Cell Physiol Biochem 2018;48:838 –846
Conclusion: Lower expression of miR-374a is associated with poor prognosis and miR-374a improves tumor biological behavior in bladder cancer cells, suggesting that miR-374a might be a novel small-molecule therapeutic target.Cell Physiol Biochem 2018;48:815 –826
Conclusions: Our data revealbiological and functional interactions between immunotherapy and radiotherapy through the miR-195/-16 family regulatory cascade.Cell Physiol Biochem 2018;48:801 –814
Publication date: November 2018Source: Clinica Chimica Acta, Volume 486Author(s): Jieli Li, Jing Ma, Elizabeth A. Wagar, Dong Liang, Qing H. MengAbstractBackgroundVoriconazole (VOR), an antifungal agent, is clinically monitored to guide therapeutic dosing and avoid toxicity. It is believed that measurement of serum unbound VOR provides more accurate information, especially in hypoalbuminemia patients. We developed and validated an accurate, simple and fast test with ultrafiltration and ultra-performance liquid chromatography (UPLC)-tandem mass spectrometry (MS/MS) to measure unbound VOR in human serum.MethodsThe Agilent UP...
ConclusionsLower serum UA concentrations may be associatedwith lower BMD values and higher prevalence of clinical fractures independent of potential confounders except for BMD values at each site. These findings need to be confirmed by further prospective studies.
CONCLUSIONS: Preventive programs should be implemented for industrial workers, especially young workers, workers who smoke, overweight workers, and workers with psychosomatic disease. PMID: 30019636 [PubMed - as supplied by publisher]
Abstract Rapid eye movement sleep behavior disorder (RBD) is a parasomnia, with abnormal dream-enacting behavior during the rapid eye movement (REM) sleep. RBD is either idiopathic or secondary to other neurologic disorders and medications. Dementia with Lewy bodies (DLB) is the third most common cause of dementia, and the typical clinical presentation is rapidly progressive cognitive impairment. RBD is one of the core features of DLB and may occur either in advance or simultaneously with the onset of DLB. The association between RBD with DLB is widely studied. Evidences suggest that both DLB and RBD are possibly ...
Conclusions: The current findings indicate that MST1 participates in SAH-induced BBB disruption and white matter fiber damage via the downstream NF-κB-MMP-9 signaling pathway. Therefore, MST1 antagonists may serve as a novel therapeutic target to prevent early brain injury in SAH patients. PMID: 30018671 [PubMed - in process]
More News: Blogging | Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Colon Cancer | Colorectal Cancer | Heart | Heart Disease | Hormonal Therapy | Hormone Replacement Therapy | Hormones | Insomnia | Men | Menopause | Orthopaedics | Osteoporosis | Ovarian Cancer | Ovaries | Primary Care | Sleep Disorders | Sleep Medicine | Statistics | Stroke | Study | Women